RAYNOR DANIEL 4
4 · ANI PHARMACEUTICALS INC · Filed Mar 14, 2018
Insider Transaction Report
Form 4
RAYNOR DANIEL
Director
Transactions
- Sale
Common Stock
2018-03-12$62.88/sh−7,928$498,513→ 316,254 total(indirect: See Footnote) - Sale
Common Stock
2018-03-13$61.81/sh−14,000$865,340→ 302,254 total(indirect: See Footnote) - Sale
Common Stock
2018-03-14$62.02/sh−1,919$119,016→ 296,218 total(indirect: See Footnote) - Sale
Common Stock
2018-03-13$62.59/sh−4,117$257,683→ 298,137 total(indirect: See Footnote)
Footnotes (5)
- [F1]This transaction was executed in multiple trades at prices ranging from $62.8223 to $63.037. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]Held by Argentum Capital Partners II. L.P., which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1)
- [F3]This transaction was executed in multiple trades at prices ranging from $61.51 to $62.17. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]This transaction was executed in multiple trades at prices ranging from $62.50 to $63.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F5]This transaction was executed in multiple trades at prices ranging from $62.00 to $62.09. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.